The DOI matches its Crossref record.
Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor.
Abstract
Suppression of immune-mediated inflammation within the normal anterior chamber (AC) of the eye is in part the result of active suppression of effector T cell activities by immunosuppressive cytokines found in aqueous humor (AqH), the fluid filling the AC. There are immunosuppressive factors found in the low m.w. fraction (< 5 kDa) of AqH, including the neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH). In seeking other factors, we now report that the neuropeptide vasoactive intestinal peptide (VIP) is also present in normal AqH. VIP immunoreactivity was found in normal rabbit eyes at a concentration of 12 +/- 1 nM. At this intraocular concentration, VIP suppressed Ag-stimulated lymph node cell (LNC) proliferation and IFN-gamma production in vitro. Although suppression of LNC proliferation was not neutralized by absorption of VIP from the low m.w. fraction of AqH, removal of VIP did neutralize suppression of IFN-gamma production by this fraction of AqH. Absorption of both VIP and alpha-MSH from this fraction of AqH permitted production of IFN-gamma by Ag-stimulated LNC that was no different than absorbing VIP alone. The low m.w. fraction of AqH absorbed of either alpha-MSH and VIP lost its ability to suppress local adoptive transfer of delayed-type hypersensitivity. The results suggest that VIP is an important immunosuppressive neuropeptide in AqH. Neuropeptides play an important role in ocular immune privilege and creation of an intraocular immunosuppressive microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal
Kaliński, P., Hilkens, C. M. U., Wierenga, E. A., & Kapsenberg, M. L. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01547-9 · Cited by 933
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807
Self-citationSee no evil, hear no evil, do no evil: the lessons of immune privilege
Niederkorn, J. Y. (2006) · Nature Immunology · doi:10.1038/ni1328 · Cited by 447
The Significance of Vasoactive Intestinal Peptide in Immunomodulation
Delgado, M., Pozo, D., & Ganea, D. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.7 · Cited by 412
Shechter, R., London, A., & Schwartz, M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3391 · Cited by 403
Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host Interactions
Callegan, M. C., Engelbert, M., Parke, D. W., Jett, B. D., & Gilmore, M. S. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.1.111-124.2002 · Cited by 385
CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance
Griffith, T. S., Yu, X., Herndon, J. M., Green, D. R., & Ferguson, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80305-2 · Cited by 382
Sonoda, K.-H., Exley, M., Snapper, S., Balk, S. P., & Stein-Streilein, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.9.1215 · Cited by 354
Taylor, A. W. (2009) · Eye · doi:10.1038/eye.2008.382 · Cited by 253
Self-citationSTEIN-STREILEIN, J., & STREILEIN, J. W. (2002) · International Reviews of Immunology · doi:10.1080/08830180212066 · Cited by 218
Self-citationImmune response following intraocular delivery of recombinant viral vectors
Bennett, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302030 · Cited by 111
Immune regulation and the eye.
Stein-Streilein, J. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.08.002 · Cited by 99
Sonoda, K., Sakamoto, T., Qiao, H., Hisatomi, T., Oshima, T., Tsutsumi‐Miyahara, C., Exley, M., Balk, S. P., Taniguchi, M., & Ishibashi, T. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02239.x · Cited by 87
Metadata
- Authors
- Taylor, A. W., Streilein, J. W., & Cousins, S. W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-08-01
- Volume
- 153
- Issue
- 3
- Pages
- 1080-1086
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1709882622
- Cited by
- 204
- References
- 0
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.